Compare NIO & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NIO | RDY |
|---|---|---|
| Founded | 2014 | 1984 |
| Country | China | India |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 11.6B |
| IPO Year | 2018 | N/A |
| Metric | NIO | RDY |
|---|---|---|
| Price | $4.78 | $13.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $6.73 | ★ $16.90 |
| AVG Volume (30 Days) | ★ 39.3M | 1.1M |
| Earning Date | 11-25-2025 | 01-22-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | N/A | ★ 9.95 |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $10,189,444,895.00 | $3,851,623,984.00 |
| Revenue This Year | $33.27 | $6.12 |
| Revenue Next Year | $50.24 | $2.58 |
| P/E Ratio | ★ N/A | $17.57 |
| Revenue Growth | ★ 14.90 | 14.10 |
| 52 Week Low | $3.02 | $12.26 |
| 52 Week High | $8.02 | $16.17 |
| Indicator | NIO | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 37.96 | 44.09 |
| Support Level | $4.95 | $13.66 |
| Resistance Level | $5.38 | $14.16 |
| Average True Range (ATR) | 0.19 | 0.15 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 3.33 | 30.30 |
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.